FDA Panel Opens the Door to Peptides Despite Pushback

A Major Shift for Peptide Medicine

The Food and Drug Administration’s Pharmacy Compounding Advisory Committee has taken a significant step toward expanding access to peptide therapies, recommending that six of seven peptides under review be added to the agency’s 503A Bulks List. If ultimately accepted by the FDA, the decision would allow licensed compounding pharmacies to prepare these substances for patients with valid prescriptions, opening the door to treatments that supporters believe could benefit millions of Americans.

In the author’s view, peptides have proven to be an extraordinarily useful class of compounds with the potential to improve recovery, reduce inflammation, improve metabolic health, and provide physicians with additional tools for treating patients. While many in the medical community remain cautious, this recommendation represents an important step toward bringing these therapies into a more regulated and medically supervised environment rather than leaving patients to rely on an unregulated gray market.

The committee’s recommendations were made despite strong opposition from FDA career scientists, who argued there is insufficient evidence demonstrating the safety and effectiveness of the peptides under consideration. Nevertheless, committee members ultimately concluded that six of the seven compounds should move forward for potential legal compounding. The FDA is not obligated to accept the recommendations, but the votes represent a significant victory for peptide advocates.

Six Peptides Move Forward

The committee voted to recommend adding six peptides to the list of substances that compounding pharmacies may prepare.

The four peptides approved during the first day of deliberations were BPC-157, KPV, TB-500 and MOTS-c. On the second day, committee members also voted in favor of Epitalon and Semax. The only peptide rejected was Emideltide.

Each of the approved peptides has attracted attention for different potential applications.

BPC-157 is perhaps the best known. Supporters say it may promote healing of tendons, ligaments, muscles, joints and the digestive tract while reducing inflammation. It has become especially popular among athletes and patients recovering from orthopedic injuries.

TB-500 has been promoted for muscle recovery, wound healing, tissue repair and improved mobility. It is often discussed alongside BPC-157 because many users believe the two peptides complement each other during recovery from injuries.

KPV has primarily been studied for its anti-inflammatory properties. Advocates believe it may help patients suffering from inflammatory bowel disorders, skin inflammation and other inflammatory conditions.

MOTS-c has generated interest because of its potential effects on metabolism, mitochondrial function, insulin sensitivity, exercise recovery and healthy aging.

Semax has been promoted for migraine treatment and cognitive support, while Epitalon has attracted attention among longevity researchers for its possible role in healthy aging. Although supporters point to encouraging research and patient experiences, many of these applications remain under investigation and have not undergone the traditional FDA drug approval process.

The One Peptide That Failed

The committee drew the line at Emideltide.

The synthetic peptide had been proposed for potential treatment of opioid withdrawal, chronic insomnia and narcolepsy. After reviewing the available evidence, the committee narrowly voted against recommending it for inclusion on the compounding list. The vote was close, with six members voting in favor, seven voting against and one abstaining.

Committee member Kevin Zacharoff explained his reasoning by saying, “It’s impossible for me to not take the FDA’s recommendations at heart with respect to safety and efficacy.” His comments reflected concerns shared by several members who believed the available evidence did not justify moving forward with Emideltide.

Kennedy Has Championed Peptides

The committee’s recommendations also represent an important policy victory for Health and Human Services Secretary Robert F. Kennedy Jr.

Kennedy has publicly described himself as “a big fan” of peptides and has criticized restrictions that pushed many consumers toward an unregulated gray market. Reuters reported that Kennedy has personally used peptides and has argued that Americans already have access to these products through unofficial channels. The committee’s recommendation would instead move many of these therapies into a regulated system where physicians can prescribe them and licensed pharmacies can compound them.

Supporters argue this approach provides greater oversight than allowing patients to purchase products marketed online as “research use only” or “not for human consumption.”

As committee member Haleem Mohammed explained, “We didn’t approve a drug. Nobody put a finished product on a shelf. We took a decision that patients are already making, and we try to keep it inside a system that has rules and regulations.”

FDA Scientists Remain Concerned

Despite the committee’s recommendations, FDA staff repeatedly warned that important scientific questions remain unanswered.

Agency scientists argued that the available clinical studies are generally small and lack sufficient evidence to establish safety and effectiveness. They also warned that there is no standardization across the marketplace, meaning products sold under identical peptide names may actually contain different molecular structures.

FDA official Russell Wesdyk emphasized that even identifying exactly which compound a patient receives can be difficult because of inconsistent naming conventions and quality standards. He urged committee members to consider the need for stronger regulatory guardrails before expanding access.

Critics have also expressed concern that several committee members have professional ties to peptide clinics or businesses. The Department of Health and Human Services has responded that all members underwent the same ethics review and vetting process required for FDA advisory committee service.

A New Chapter for Peptide Therapy

Whether the FDA ultimately adopts the committee’s recommendations remains to be seen, but the vote marks one of the most significant developments yet for peptide medicine in the United States.

Rather than treating peptides solely as products circulating through an unregulated gray market, the committee has recommended bringing many of them into a system that includes physician oversight, licensed compounding pharmacies and established regulatory controls. Supporters believe that approach will improve patient safety while allowing additional research and clinical experience to determine which peptides ultimately prove most beneficial.

For advocates, the committee’s recommendation represents more than a regulatory change. It signals growing recognition that peptide therapies deserve serious scientific evaluation and may become an increasingly important part of modern medicine in the years ahead.

Quick comparison